Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Chrysalis Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,869,579

2,421 payments

Through program year 2025, Chrysalis Clinical Research is reported as receiving $2,869,579 in research payments, across 2,421 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $480,557 118
2024 Research $277,055 261
2023 Research $727,509 66
2022 Research $194,694 301
2021 Research $396,512 1,366
2020 Research $385,271 196
2019 Research $407,980 113

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novo Nordisk AS $831,983 2,065 payments
  2. Pfizer Inc. $760,088 53 payments
  3. GlaxoSmithKline, LLC. $345,390 97 payments
  4. Hoffmann-La Roche Limited $276,727 8 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $252,077 11 payments
  6. OptiNose US, Inc. $92,687 14 payments
  7. Roche Products Limited $73,987 33 payments
  8. Allergan Inc. $64,927 26 payments
  9. Otonomy, Inc. $57,895 10 payments
  10. Sanofi US Services Inc. $49,524 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2 Randomized Doubleblind Placebo Controlled Dose Ranging Dose Finding Parallel Group Study to Assess Efficacy and Safety of Pf07081532 and Open Label Oral Semaglutide in Adults With Type 2 Diabetes Mellitus T2dm Inadequately Controlled on Metformin and Separately Pf07081532 Compared to Matching Placebo in Adults With Obesity But Without T2dm $634,394 33 payments
  2. A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $314,802 91 payments
  3. Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity $276,727 8 payments
  4. Nn9536-4375 $233,719 53 payments
  5. Obesity Long term safety in patients with CV risk $188,761 5 payments
  6. Nn9535-4801 $117,350 419 payments
  7. A Phase 2A Randomized Doubleblind Sponsoropen Placebocontrolled Parallel Group Doseranging Study of Pf07976016 to Assess Safety and Efficacy in Adult Participants With Obesity $110,311 17 payments
  8. Nn9536-4374 $101,938 39 payments
  9. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $84,311 92 payments
  10. Nn1436-4477 $75,031 406 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record